UniQure (QURE) Shares Rise 78% Following FDA Acceptance of AMT-130 Clinical Data
Shares of UniQure (NASDAQ: QURE) surged by 78.44%, closing at $48.16, after the FDA accepted data analysis from its Phase I clinical trial for AMT-130 and agreed to support a near-term BLA submission.
Tickers: $QURE
Topics: biotech gene-therapy huntingtons-disease